PhiCal® Calprotectin ELISA Kit

For the in vitro determination of calprotectin (MRP 8/14, S100A8/A9) in stool

[PhiCal®: registered German trademark of Immundiagnostik AG]

Gültig ab / Valid from 23.08.2013

Immundiagnostik AG, Stubenwald-Allee 8a, D-64625 Bensheim
Tel.: +49 6251 70190-0   Fax: +49 6251 849430
e.mail: info@immundiagnostik.com   www.immundiagnostik.com
**PhiCal® Calprotectin ELISA Kit**

*For the in vitro determination of calprotectin (MRP 8/14, S100A8/A9) in stool*

[PhiCal®: registered German trademark of Immundiagnostik AG]

Valid from 23.08.2013

REF K 6967

Immundiagnostik AG
# Table of Contents

1. **INTENDED USE** ........................................................................................................... 18

2. **CLINICAL RELEVANCE** ............................................................................................. 18

3. **MATERIAL SUPPLIED** ............................................................................................... 19

4. **MATERIAL REQUIRED BUT NOT SUPPLIED** .......................................................... 19

5. **PREPARATION AND STORAGE OF REAGENTS** ...................................................... 20

6. **SPECIMEN COLLECTION AND PREPARATION** ...................................................... 21
   - Sample stability and storage ....................................................................................... 21
   - Extraction of the stool sample ................................................................................... 21
   - Dilution of samples ................................................................................................... 22

7. **ASSAY PROCEDURE** .................................................................................................. 22
   - Principle of the test .................................................................................................. 22
   - Test procedure ......................................................................................................... 23

8. **RESULTS** .................................................................................................................... 24

9. **LIMITATIONS** ........................................................................................................... 24

10. **QUALITY CONTROL** ................................................................................................ 25
    - Normal range ........................................................................................................... 25
    - Reference ranges for fecal calprotectin in children ............................................... 25

11. **PERFORMANCE CHARACTERISTICS** .................................................................... 26
    - Precision and reproducibility ................................................................................. 26
    - Spiking Recovery .................................................................................................... 27
    - Analytical Sensitivity ............................................................................................... 27
    - Specificity ................................................................................................................. 27
    - Dilution recovery ..................................................................................................... 28

12. **PRECAUTIONS** ........................................................................................................ 28

13. **TECHNICAL HINTS** .................................................................................................. 29

14. **GENERAL NOTES ON THE TEST AND TEST PROCEDURE** ............................... 29

15. **REFERENCES** ........................................................................................................... 30
    - General literature .................................................................................................... 30
    - Publications using Immundiagnostik Calprotectin ELISA ....................................... 30
1. INTENDED USE
The described PhiCal® Calprotectin ELISA is intended for the quantitative determination of calprotectin (MRP (8/14, S100A8/A9) in stool. For in vitro diagnostic use only.

2. CLINICAL RELEVANCE
Alternative names:
- Calgranulin A: MRP8, S100A8, CP-10 (in mouse)
- Calgranulin B: MRP14, S100A9,
- MRP8/14: L1, (p8,14), p34

Calprotectin is a calcium-binding protein secreted predominantly by neutrophils and monocytes. Fecal calprotectin is a marker for neoplastic and inflammatory gastrointestinal diseases.

It is often difficult to distinguish between irritable bowel syndrome and chronic inflammatory bowel disease. This leads in many cases to extensive and unnecessary colonoscopic examinations. The calprotectin test allows clear differentiation between the two patient groups. Fecal calprotectin levels correlate significantly with histologic and endoscopic assessment of disease activity in Morbus Crohn’s disease and ulcerative colitis as well as with the fecal excretion of indium-111-labelled neutrophilic granulocytes that has been suggested as the “gold standard” of disease activity in inflammatory bowel disease. However, measuring 111-indium-labeled granulocytes is very costly (patient’s hospitalization, analysis and disposal of isotopic material) and is connected with radioactive exposition of the patients. For this reason, a repeated application to children and pregnant women is not recommended.

Elevated levels of calprotectin are a much better predictor of relapse than standard inflammatory markers (CRP, ESR HB). Comparing this marker with standard fecal occult blood screening in colorectal cancer demonstrates clearly the diagnostic advantages of the fecal calprotectin test. The parameter is of a high diagnostic value: if the calprotectin level in stool is low, the probability is high that no organic intestinal disease exists.

Indications
- Marker for acute inflammation
- Estimation of gastrointestinal inflammation degree
- Parameter for monitoring Morbus Crohn’s disease, Colitis ulcerosa or the patient’s status after removal of polyps.
- Discrimination between patients with inflammatory bowel disease (acute Morbus Crohn’s disease and ulcerative colitis) and irritable bowel syndrome when using a fecal test system
3. MATERIAL SUPPLIED

<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>Label</th>
<th>Kit components</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>K 6967MTP</td>
<td>PLATE</td>
<td>Holder with precoated strips</td>
<td>12 x 8 wells</td>
</tr>
<tr>
<td>K 6967WP</td>
<td>WASHBUF</td>
<td>ELISA wash buffer concentrate 10x</td>
<td>2 x 100 ml</td>
</tr>
<tr>
<td>K 6967EP</td>
<td>EXBUF</td>
<td>Extraction buffer concentrate 2.5x</td>
<td>1 x 100 ml</td>
</tr>
<tr>
<td>K 6967PV</td>
<td>SAMPLEBUF</td>
<td>Sample dilution buffer, ready to use</td>
<td>1 x 100 ml</td>
</tr>
<tr>
<td>K 6967CAL</td>
<td>CAL</td>
<td>Calprotectin calibrator, lyophilized</td>
<td>2 vials</td>
</tr>
<tr>
<td>K 6967KO1</td>
<td>CTRL</td>
<td>Control, lyophilized (see specification for range)</td>
<td>2 x 1 vial</td>
</tr>
<tr>
<td>K 6967KO2</td>
<td>CTRL</td>
<td>Control, lyophilized (see specification for range)</td>
<td>2 x 1 vial</td>
</tr>
<tr>
<td>K 6967K</td>
<td>CONJ</td>
<td>Conjugate, ready to use</td>
<td>15 ml</td>
</tr>
<tr>
<td>K 6967TMB</td>
<td>SUB</td>
<td>TMB substrate (Tetramethylbenzidine), ready to use</td>
<td>15 ml</td>
</tr>
<tr>
<td>K 6967AC</td>
<td>STOP</td>
<td>ELISA stop solution, ready to use</td>
<td>15 ml</td>
</tr>
</tbody>
</table>

4. MATERIAL REQUIRED BUT NOT SUPPLIED

- Ultra pure water*
- Laboratory balance
- Precision pipettors calibrated and tips to deliver 10-1000 µl
- Foil to cover the microtiter plate
- Multi-channel dispenser or repeating dispenser
- Centrifuge, 3000 g
- Vortex mixer
- Standard laboratory glass or plastic vials, cups, etc.
- Microtiter plate reader

* Immundiagnostik AG recommends the use of Ultra Pure Water (Water Type 1; ISO 3696), which is free of undissolved and colloidal ions and organic molecules (free of particles > 0.2 µm) with an electrical conductivity of 0.055 µS/cm at 25 °C (≤ 18.2 MΩ cm).
5. PREPARATION AND STORAGE OF REAGENTS

- To run assay more than once, ensure that reagents are stored at conditions stated on the label. **Prepare only the appropriate amount necessary for each run.** The kit can be used up to 4 times within the expiry date stated on the label.

- Reagents with a volume less than **100 µl** should be centrifuged before use to avoid loss of volume.

- The **ELISA wash buffer concentrate** (WASHBUF) should be diluted **1:10 in ultra pure water** before use (100 ml concentrate + 900 ml ultra pure water), mix well. Crystals could occur due to high salt concentration in the stock solutions. The crystals must be redissolved at room temperature or at 37°C before dilution of the buffer solutions. The **buffer concentrate** is stable at **2 - 8°C** until the expiry date stated on the label. **Diluted buffer solution (wash buffer)** can be stored in a closed flask at **2 - 8°C for one month**.

- Use **100 µl** of **SAMPLEBUF** (sample dilution buffer) as **BLANK**. Pipet into the respective well.

- The **EXBUF** (extraction buffer concentrate) must be diluted with ultra pure water **1:2.5** before use (100 ml EXBUF + 150 ml ultra pure water), mix well. Crystals could occur due to high salt concentration in the stock solutions. Before dilution, the crystals must be redissolved at 37°C in a water bath. The **buffer concentrate** is stable at **2 - 8°C** until the expiry date stated on the label. **Diluted buffer solution** can be stored in a closed flask at **2 - 8°C for three months**.

- The lyophilized **CAL** (calibrator) and **CTRL** (controls) are stable at **2 - 8°C** until the expiry date stated on the label. The **CAL** (calibrator) and **CTRL** (controls) must be reconstituted with **500 µl of ultra pure water**. Allow the vial content to dissolve for 10 minutes at room temperature, and mix thoroughly by gentle inversion to insure complete reconstitution. **Reconstituted calibrator and controls can be stored at 2 - 8°C for 4 weeks**.

- All other test reagents are ready to use. Test reagents are stable until the expiry date (see label of test package) when stored at **2 - 8°C**.
6. SPECIMEN COLLECTION AND PREPARATION

Sample stability and storage

Raw stool
Calprotectin in stool is described to be stable for approximately 6 days. Nevertheless, we recommend to store the samples for not more than 48 h at 2-8 °C. Long term storage is recommended at -20 °C. Allow frozen samples to thaw slowly, preferably at 2-8 °C over night and warm the samples to room temperature before analysis.

(Poullis A et al. (2002) Aliment Pharmacol Thr 16:675-681)

Stool extracts
Stool extract is stable at 2-8 °C for nine days.

Extraction of the stool sample

Diluted extraction buffer is used as a sample extraction buffer. We recommend the following sample preparation:

1a. Stool Sample Application System (SAS) (Cat. No.: K 6998SAS)

Stool sample tube – Instruction for use
Please note that the dilution factor of the final stool suspension depends on the used amount of stool sample and the volume of the buffer.

SAS with 0.75 ml Buffer:
Applied amount of stool: 15 mg
Buffer Volume: 0.75 ml
Dilution Factor: 1:50

Please follow the instructions for the preparation of stool samples using the SAS as follows:

a) The raw Stool Sample has to be thawed. For remarkably inhomogeneous samples we recommend a mechanical homogenisation using an applicator, inoculation loop or similar device.

b) Fill the empty sample tube with 0.75 ml of ready-to-use extraction buffer before using it with the sample. Important: Allow the extraction buffer to reach room temperature.

c) Unscrew the tube (yellow part of cap) to open. Insert yellow dipstick into sample. The lower part of the dipstick exhibits notches which need to be covered completely with stool after inserting it into the sample. Place dipstick
back into the tube. When putting the stick back into the tube, excess material will be stripped off and leave 15 mg of sample to be diluted. Screw tightly to close the tube.

d) Shake the tube well until no stool sample remains in the notches. Important: Please make sure that you have a maximally homogenous suspension after shaking. Especially with more solid samples, soaking the sample in the tube with buffer for app. 10 minutes improves the result.

e) Allow sample to stand for app. 10 minutes until sediment has settled down. Floating material like shells of grains can be neglected.

f) Carefully unscrew the complete cap of the tube including the turquoise ring plus the dipstick. Discard cap and dipstick. Make sure, the sediment will not be dispersed again.

1b. Sample preparation kit from Roche Diagnostics, Mannheim, Germany (Cat. No. 10 745 804 322)

Alternatively, other stool sample preparation kits (e.g. Sample preparation kit from Roche Diagnostics, Mannheim, Germany) can be used. In the Roche sample preparation kit, 100 mg of stool sample are suspended in 5 ml of extraction buffer using a vibrator mixer (e.g. Vortex mixer). Allow sample to stand for app. 10 minutes until sediment has settled down. Floating material like shells of grains can be neglected.

Dilution I (1a. or 1b.)  1:50

Dilution of samples

The suspension of sample preparation procedure 1a. or 1b. (dilution I) is diluted \textbf{1:50} with \textit{SAMPLEBUF} (sample dilution buffer). For example:

\[ 20 \mu l \text{ supernatant (dilution I)} + 980 \mu l \text{ SAMPLEBUF} = 1:50 \text{ (dilution II)} \]

For analysis, pipet \textbf{100 \mu l} of the supernatant of \textit{dilution II} per well.

7. ASSAY PROCEDURE

Principle of the test

The assay utilizes the two-site “sandwich” technique with two selected monoclonal antibodies that bind to human calprotectin.

Calibrator, controls and diluted patient samples which are assayed for human calprotectin are added to wells of microplate coated with a high affine monoclonal anti-human calprotectin antibody. During the first incubation step, calprotectin in the
samples is bound by the immobilized antibody. Then a peroxidase labeled conjugate
is added to each well and the following complex is formed: capture antibody - hu-
man calprotectin – Peroxidase conjugate. Tetramethylbenzidine (TMB) is used as a
substrate for peroxidase. Finally, an acidic stop solution is added to terminate the
reaction. The color changes from blue to yellow. The intensity of the yellow color is
directly proportional to the calprotectin concentration of sample. Samples are quant-
ified by referring their optical density to a lot-dependent master calibration curve
and the use of the calibrator that is run with each test.

**Test procedure**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Bring all reagents and samples to room temperature (15 - 30 °C) and mix well.</td>
</tr>
<tr>
<td>2.</td>
<td>Mark the <strong>positions of BLANK / CAL / CTRL / SAMPLE</strong> (blank / calibrator / controls / sample) in duplicate on a protocol sheet.</td>
</tr>
<tr>
<td>3.</td>
<td>Take as many <strong>microtiter strips</strong> as needed from kit. Store unused strips covered at 2 - 8 °C. Strips are stable until expiry date stated on the label.</td>
</tr>
<tr>
<td>4.</td>
<td>Add <strong>100 µl of BLANK / CAL / CTRL / SAMPLE</strong> (blank / calibrator / controls / sample) in duplicate into respective well.</td>
</tr>
<tr>
<td>5.</td>
<td>Cover plate tightly and <strong>incubate for 30 minutes at room temperature</strong> (15 - 30 °C).</td>
</tr>
<tr>
<td>6.</td>
<td>Aspirate the contents of each well. Wash each well <strong>5 x with 250 µl of wash buffer</strong>. After the final washing step, the inverted microtiter plate should be firmly tapped on absorbent paper.</td>
</tr>
<tr>
<td>7.</td>
<td>Add <strong>100 µl CONJ</strong> (conjugate) into each well.</td>
</tr>
<tr>
<td>8.</td>
<td>Cover plate tightly and incubate for <strong>30 minutes at room temperature</strong> (15 - 30 °C).</td>
</tr>
<tr>
<td>9.</td>
<td>Aspirate the contents of each well. Wash each well <strong>5 x with 250 µl of wash buffer</strong>. After the final washing step, the inverted microtiter plate should be firmly tapped on absorbent paper.</td>
</tr>
<tr>
<td>10.</td>
<td>Add <strong>100 µl of SUB</strong> (substrate) into each well.</td>
</tr>
<tr>
<td>11.</td>
<td>Incubate for <strong>10 - 20 minutes at room temperature</strong> (15 - 30 °C) in the dark*.</td>
</tr>
<tr>
<td>12.</td>
<td>Add <strong>100 µl of STOP</strong> (stop solution) into each well, mix thoroughly.</td>
</tr>
</tbody>
</table>
13. Determine **absorption immediately** with an ELISA reader at **450 nm** against 620 nm (or 690 nm) as a reference. If no reference wavelength is available, read only at 450 nm. If the extinction of the highest standard exceeds the range of the photometer, absorption must be measured immediately at **405 nm** against 620 nm as a reference.

* The intensity of the color change is temperature sensitive. We recommend to observe the color change and to stop the reaction upon good differentiation.

8. RESULTS

For result evaluation, please use a four parametric logit-log model based on the standard curve of the respective kit lot and the calibrator value (CAL). All essential information on the standard curve is provided on the QC data sheet of the respective product lot.

The calibration curve can be expressed either by the concentration of each standard with its corresponding optical density or by the four parameters A, B, C and D. In both cases the optical density of the calibrator (CAL) is essential.

Depending on your evaluation software program, either the one or the other kind of data described above should be entered.

**Caution:** Please make sure that all parameters and values are transferred accurately into your software as minor deviations can cause severe errors during evaluation.

The plausibility of the pairs of values should be examined before the automatic evaluation of the results. If this option is not available with the used program, a control of the paired values should be done manually.

**Stool samples**

The obtained calprotectin levels of the stool samples have to be multiplied with the dilution factor of 2500 (dilution I x dilution II).

9. LIMITATIONS

Samples which cannot be clearly interpreted (e.g. because of high coefficients of variation of replicates) should be measured again.
10. QUALITY CONTROL

Immundiagnostik recommends the use of external controls for internal quality control, if possible.

Control samples should be analysed with each run. Results, generated from the analysis of control samples, should be evaluated for acceptability using appropriate statistical methods. The results for the patient samples may not be valid if within the same assay one or more values of the quality control sample are outside the acceptable limits.

Normal range

1 g stool is equivalent to 1 ml.

- The median value in healthy adults is about 25 mg/kg.
- Samples giving values above 50 mg/kg are regarded as positive.

We recommend each laboratory to establish its own norm concentration range.

Note: Many confounding factors can cause increased levels of fecal calprotectin in the absence of IBD or IBD in a quiescent disease phase, e.g. use of NSAIDs (non steroidal anti inflammatory drugs), any intercurrent gastrointestinal infection, and the presence of malignancies. These factors should be considered in the interpretation of the test results and therapy of IBD. *

* D’Haens et al. Inflamm Bowel Dis, 2012; van Rheenen et al. BMJ, 2010

Reference ranges for fecal calprotectin in children


Method: 302 apparently healthy children, age 0-12 years, in Kampala, Uganda, were tested for faecal Calprotectin concentration.

Table 1: Faecal Calprotectin concentration in apparently healthy children by age.

<table>
<thead>
<tr>
<th>Age</th>
<th>Number</th>
<th>Median faecal calprotectin [mg/kg]</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 3 months</td>
<td>14 (4.6)</td>
<td>345 (195 - 621)</td>
</tr>
<tr>
<td>3 - 6 months</td>
<td>13 (4.3)</td>
<td>278 (85 - 988)</td>
</tr>
<tr>
<td>6 - 12 months</td>
<td>27 (8.9)</td>
<td>183 (109 - 418)</td>
</tr>
<tr>
<td>1 - 4 years</td>
<td>89 (29.5)</td>
<td>75 (53 - 119)</td>
</tr>
<tr>
<td>4 - 12 years</td>
<td>159 (52.6)</td>
<td>28 (25 - 35)</td>
</tr>
</tbody>
</table>

Conclusion: Concentrations of faecal Calprotectin among healthy children in
Uganda are comparable to those in healthy children living in high-income countries. In healthy infants faecal Calprotectin is high; in children older than 4 years faecal Calprotectin concentration is low.


**Method:** 117 healthy children age 4-17 years were tested for faecal Calprotectin concentration.

**Table 2:** Faecal Calprotectin concentration in healthy children by age.

<table>
<thead>
<tr>
<th>Age</th>
<th>Number</th>
<th>Median faecal calprotectin [mg/kg]</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 - 6 years</td>
<td>27</td>
<td>28.2</td>
</tr>
<tr>
<td>7 - 10 years</td>
<td>30</td>
<td>13.5</td>
</tr>
<tr>
<td>11 - 14 years</td>
<td>27</td>
<td>9.9</td>
</tr>
<tr>
<td>15 - 17 years</td>
<td>33</td>
<td>14.6</td>
</tr>
</tbody>
</table>

**Conclusion:** The suggested cut-off level for adults (< 50 mg/kg) can be used for children aged 4-17 years.

### 11. PERFORMANCE CHARACTERISTICS

**Precision and reproducibility**

**Intra-Assay (n = 20)**

<table>
<thead>
<tr>
<th>Sample</th>
<th>Calprotectin [mg/l]</th>
<th>CV [%]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>89.2</td>
<td>5.6</td>
</tr>
<tr>
<td>2</td>
<td>229.1</td>
<td>3.2</td>
</tr>
</tbody>
</table>

**Inter-Assay (n = 12)**

<table>
<thead>
<tr>
<th>Sample</th>
<th>Calprotectin [mg/l]</th>
<th>CV [%]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>107.8</td>
<td>4.4</td>
</tr>
<tr>
<td>2</td>
<td>476.1</td>
<td>8.9</td>
</tr>
</tbody>
</table>
**Spiking Recovery**

Two samples were spiked with three different calprotectin concentrations and measured using this assay. (n = 2)

<table>
<thead>
<tr>
<th>Sample</th>
<th>Unspiked Sample [µg/ml]</th>
<th>Spike [µg/ml]</th>
<th>Calprotectin expected [ng/ml]</th>
<th>Calprotectin measured [ng/ml]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>18</td>
<td>10.5</td>
<td>28.5</td>
<td>29.6</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>17.5</td>
<td>35.5</td>
<td>35.6</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>40.5</td>
<td>58.5</td>
<td>59.3</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>63.3</td>
<td>81.3</td>
<td>83.2</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>173.2</td>
<td>191.2</td>
<td>188.7</td>
</tr>
<tr>
<td>2</td>
<td>20.7</td>
<td>10.5</td>
<td>31.2</td>
<td>33.3</td>
</tr>
<tr>
<td></td>
<td>20.7</td>
<td>17.5</td>
<td>38.2</td>
<td>41.0</td>
</tr>
<tr>
<td></td>
<td>20.7</td>
<td>40.5</td>
<td>61.2</td>
<td>62.7</td>
</tr>
<tr>
<td></td>
<td>20.7</td>
<td>63.3</td>
<td>84.0</td>
<td>90.8</td>
</tr>
</tbody>
</table>

**Analytical Sensitivity**

The detection limit was set as $B_0 + 6$ SD. The Zero-standard was measured 22 times. The values were estimated in relation to the concentration of the calibration curve and resulted in

- a detection limit of 2.099 ng/ml without consideration of the sample dilution factor
- a detection limit of 5.2475 mg/l with consideration of the sample dilution factor

**Specificity**

No cross reactivity was observed to the following plasma proteins:

- Lysozyme 0%
- PMN-Elastase 0%
- Myeloperoxidase 0%
- Lactoferrin 0%
Dilution recovery

Three patient samples were diluted with SAMPLEBUF and analyzed. The results are shown below (n = 3):

<table>
<thead>
<tr>
<th>Sample</th>
<th>Dilution</th>
<th>Calprotectin expected [mg/l]</th>
<th>Calprotectin measured [mg/l]</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>1:2500</td>
<td>820</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:5000</td>
<td>410</td>
<td>425</td>
</tr>
<tr>
<td></td>
<td>1:10000</td>
<td>205</td>
<td>192</td>
</tr>
<tr>
<td>B</td>
<td>1:2500</td>
<td>1120</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:5000</td>
<td>560</td>
<td>561</td>
</tr>
<tr>
<td></td>
<td>1:10000</td>
<td>280</td>
<td>266.5</td>
</tr>
<tr>
<td>C</td>
<td>1:1250</td>
<td>321.5</td>
<td>344.0</td>
</tr>
<tr>
<td></td>
<td>1:2500</td>
<td>160.8</td>
<td>157.8</td>
</tr>
<tr>
<td></td>
<td>1:5000</td>
<td>80.4</td>
<td>80.0</td>
</tr>
<tr>
<td></td>
<td>1:10000</td>
<td>40.2</td>
<td>39.7</td>
</tr>
<tr>
<td></td>
<td>1:20000</td>
<td>20.1</td>
<td>17.6</td>
</tr>
<tr>
<td></td>
<td>1:40000</td>
<td>10.0</td>
<td>9.5</td>
</tr>
<tr>
<td></td>
<td>1:80000</td>
<td>5.0</td>
<td>5.0</td>
</tr>
<tr>
<td></td>
<td>1:160000</td>
<td>5.0</td>
<td>5.0</td>
</tr>
</tbody>
</table>

12. PRECAUTIONS

- All reagents in the kit package are for in vitro diagnostic use only.
- Control samples should be analyzed with each run.
- Human materials used in kit components were tested and found to be negative for HIV, Hepatitis B and Hepatitis C. However, for safety reasons, all kit components should be treated as potentially infectious.
- Kit reagents contain sodium azide or Proclin as bactericides. Sodium azide and Proclin are toxic. Substrates for the enzymatic color reactions are toxic and carcinogenic. Avoid contact with skin or mucous membranes.
- The stop solution consists of diluted sulphuric acid, a strong acid. Although diluted, it still must be handled with care. It can cause burns and should be
handled with gloves, eye protection, and appropriate protective clothing. Any spill should be wiped out immediately with copious quantities of water. Do not breathe vapour and avoid inhalation.

13. TECHNICAL HINTS

• Do not interchange different lot numbers of any kit component within the same assay. Furthermore we recommend not to assemble wells of different microtiter plates for analysis, even if they are of the same batch as wells from already opened microtiter plates are exposed to different conditions as sealed ones.

• Reagents should not be used beyond the expiration date stated on kit label.

• Substrate solution should remain colourless until use.

• To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.

• Avoid foaming when mixing reagents.

• The assay should always be performed according the enclosed manual.

14. GENERAL NOTES ON THE TEST AND TEST PROCEDURE

• This assay was produced and distributed according to the IVD guidelines of 98/79/EC.

• Quality control guidelines should be followed.

• Incubation time, incubation temperature and pipetting volumes of the components are defined by the producer. Any variation of the test procedure, which is not coordinated with the producer, may influence the results of the test. Immundiagnostik AG can therefore not be held responsible for any damage resulting from wrong use.

• Warranty claims and complaints in respect of deficiencies must be logged within 14 days after receipt of the product. The product should be send to Immundiagnostik AG along with a written complaint.
15. REFERENCES

General literature


Publications using Immundiagnostik Calprotectin ELISA


11. Schröder, O., Naumann, M., Shastri, Y., Povse, N. & Stein, J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: com-

**Used symbols:**

- 📋 Temperature limitation
- REF Catalogue Number
- IVD In Vitro Diagnostic Medical Device
- ∑ Contains sufficient for <n> tests
- 🏷 Manufacturer
- ⌛️ Use by
- LOT Lot number